Work Here?
Overview
Adicet Bio develops cancer immunotherapies using donor-derived, allogeneic gamma delta T cells that are engineered to target and kill cancer cells. The therapy uses off-the-shelf cells instead of a patient’s own cells, making treatment faster and potentially more readily available. The product works by introducing these modified T cells into a patient, where they seek out and destroy tumor cells. Adicet Bio differentiates itself by providing an immediately available, genetically modified immune cell therapy rather than patient-specific treatments, and by focusing on gamma delta T cells, which may offer targeted anti-tumor activity with a different safety and efficacy profile. The company aims to bring these therapies to patients through commercialization, licensing, and partnerships with healthcare providers and larger pharma companies, supported by ongoing research and development and strategic initiatives like the merger with resTORbio and a substantial funding round.
About Adicet Bio
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Redwood City, California
Founded
2014
Get referred to Adicet Bio
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 5, 2026 cash was $118.2 million, funding operations into 2H 2027.
- Q3 2026 prula-cel data should cover 22 lupus patients with 12-month follow-up.
- ADI-212 filing is planned for Q3 2026, opening a new PSMA oncology path.
What critics are saying
- August 3, 2026 CMO Julie Maltzman resigned; interim coverage weakens clinical execution.
- July 2025 ADI-270 shutdown and 30% layoffs exposed brittle pipeline concentration.
- If prula-cel stalls in 2H 2026, Adicet faces another dilutive financing cycle.
What makes Adicet Bio unique
- Adicet’s prula-cel uses allogeneic gamma delta T cells, not patient-specific manufacturing.
- January 7, 2026 FDA alignment enabled outpatient prula-cel dosing in lupus patients.
- MaxCyte’s August 4, 2025 platform license supports Adicet’s gene-edited manufacturing and scale.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$321M
Above
Industry Average
Funded Over
7 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Flexible Work Hours
Paid Vacation
Paid Sick Leave
Paid Holidays
Parental Leave
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Wellness Program
Stock Price
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -2%2 year growth
↑ 3%Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference. July 22, 2026 | REDWOOD CITY, Calif.-(BUSINESS WIRE)-Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston. Details of the event are as follows: Date: Tuesday, August 11, 2026 Time: 10:30 a.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at https://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com. Adicet Bio, Inc. Investor and Media Contacts Anne Bowdidge [email protected] Penelope Belnap Precision AQ [email protected]
Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference. REDWOOD CITY, Calif.-(BUSINESS WIRE)-Jul. 21, 2026- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston. Details of the event are as follows: Date: Tuesday, August 11, 2026 Time: 10:30 a.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at https://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit its website at https://www.adicetbio.com. Adicet Bio, Inc. Investor and Media Contacts Anne Bowdidge [email protected] Penelope Belnap Precision AQ [email protected]
Adicet Bio has expanded enrollment in its Phase 1 prula-cel programme for autoimmune diseases to over 20 patients as of 31 December 2025, more than doubling since October. All seven autoimmune cohorts are now actively enrolling, including the first ANCA-associated vasculitis patient. The company has secured FDA alignment for outpatient dosing of lupus nephritis and systemic lupus erythematosus patients. Adicet is also advancing ADI-212 for metastatic castration-resistant prostate cancer, targeting a regulatory filing in the first half of 2026. An October 2025 equity raise of approximately $74.8 million has extended the company's cash runway into the second half of 2027. Multiple clinical data updates are planned throughout 2026 as Adicet works towards a pivotal trial design.
Adicet Bio (NASDAQ:ACET) announced an $80 million stock offering, pricing 70,001,000 shares at $1 each and pre-funded warrants for 10 million shares at $0.9999. The offering, expected to close by October 8, 2025, aims to bolster finances amid rapid cash burn. Jefferies and Guggenheim Securities are joint book-running managers. Adicet also reported positive results from its ADI-001 trial and halted ADI-270 development, reducing its workforce by 30% to extend cash reserves into Q4 2026.
Auspicious alliance: MaxCyte and Adicet partner to develop off-the-shelf T-cell therapies.
Adicet Bio is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Adicet Bio
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Redwood City, California
Founded
2014
Adicet Bio is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today